JPIAMR-ACTION (963864)

  https://cordis.europa.eu/project/id/963864

  Horizon 2020 (2014-2020)

  JPIAMR- ANTIMICROBIAL TRANSMISSION INTERVENTIONS

  ERA-NET to support the Joint Programming Initiative on Antimicrobial resistance (JPIAMR) (SC1-HCO-07-2020)

  antibiotics  ·  antibiotic resistance

  2021-01-01 Start Date (YY-MM-DD)

  2025-12-31 End Date (YY-MM-DD)

  € 26,311,250 Total Cost

  Description

In the past 90 years since their discovery, antibiotics have saved millions of lives from bacterial diseases. However, emerging resistance to antimicrobials now threatens many advances achieved in modern medicine. AMR is a critical global health issue tightly linked with the One Health concept, which recognises that human and animal health are inextricably linked, and that diseases are transmitted from humans to animals and vice versa. One Health also encompasses the environment as another link between humans and animals and a potential source and reservoir of AMR. Antimicrobial resistance is a growing global health concern and threatens the future treatment and health of humans and animals. In addition, AMR limits our ability to achieve several of the UN Sustainable Development Goals (SDGs). The global challenge to address AMR goes beyond the production of new antibiotics and therapies. Reducing demand for new antibiotics through public awareness, infection prevention and control, prudent and rational use of antibiotics for humans and animals, as well as effective diagnosis and surveillance of antibiotic-resistant infections and monitoring antibiotic use, are crucial when dealing with this problem globally. The transmission and spread of AMR in and between One Health compartments is complex, which emphasises the need for comprehensive interventions to reverse the trend of increasing human and animal infections resistant to treatment. The ERA-NET Cofund JPIAMR-ACTION will tackle this central challenge by supporting research and innovation for the development and testing of strategies and methodologies to reduce the transmission and spread of AMR within a full One Health spectrum. The JPIAMR-ACTION co-funded call and other activities will be instrumental in producing new innovative approaches, and advancing existing actions towards the development of new and improved interventions to inhibit or limit the development of AMR in humans, animals and the environment.

  Complicit Organisations

1 Israeli organisation participates in JPIAMR-ACTION.